Aptose Biosciences Inc. (NASDAQ:APTO – Free Report) (TSE:APS) – Equities research analysts at HC Wainwright issued their FY2024 EPS estimates for Aptose Biosciences in a report released on Wednesday, November 20th. HC Wainwright analyst J. Pantginis anticipates that the biotechnology company will earn ($1.79) per share for the year. HC Wainwright has a “Buy” rating and a $2.00 price objective on the stock. The consensus estimate for Aptose Biosciences’ current full-year earnings is ($1.79) per share. HC Wainwright also issued estimates for Aptose Biosciences’ Q4 2024 earnings at ($0.35) EPS.
Separately, StockNews.com began coverage on shares of Aptose Biosciences in a research report on Thursday, November 21st. They issued a “hold” rating for the company.
Aptose Biosciences Trading Down 3.1 %
Shares of Aptose Biosciences stock opened at $0.18 on Monday. The company has a fifty day simple moving average of $0.38 and a 200-day simple moving average of $0.60. The stock has a market cap of $3.34 million, a price-to-earnings ratio of -0.06 and a beta of 1.26. Aptose Biosciences has a 12-month low of $0.13 and a 12-month high of $2.91.
Hedge Funds Weigh In On Aptose Biosciences
An institutional investor recently bought a new position in Aptose Biosciences stock. Armistice Capital LLC acquired a new position in shares of Aptose Biosciences Inc. (NASDAQ:APTO – Free Report) (TSE:APS) during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 1,713,000 shares of the biotechnology company’s stock, valued at approximately $1,300,000. Armistice Capital LLC owned about 9.46% of Aptose Biosciences as of its most recent filing with the SEC. 26.62% of the stock is currently owned by hedge funds and other institutional investors.
Aptose Biosciences Company Profile
Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.
Recommended Stories
- Five stocks we like better than Aptose Biosciences
- Overbought Stocks Explained: Should You Trade Them?
- Abacus Life’s CEO on Cracking the Code of Longevity Returns
- When to Sell a Stock for Profit or Loss
- Elon Musk and Trump Push for Self-Driving Cars: 3 Stocks to Gain
- What is the Nikkei 225 index?
- Discover the 3 Best Performing Stocks That Went Public in 2024
Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
